Detalhe da pesquisa
1.
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.
Nature
; 567(7748): 399-404, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30867590
2.
Digital pathology for reporting histopathology samples, including cancer screening samples - definitive evidence from a multisite study.
Histopathology
; 84(5): 847-862, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38233108
3.
An international unified approach to reporting and grading invasive breast cancer. An overview of the International Collaboration on Cancer Reporting (ICCR) initiative.
Histopathology
; 82(1): 189-197, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36482273
4.
Second opinion (external specialist referral) practice of breast pathology: the Nottingham experience.
Histopathology
; 83(3): 394-405, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37356966
5.
Preoperative diagnosis of ductal carcinoma in situ of the breast over a 24-year period.
Histopathology
; 83(3): 435-442, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37356976
6.
The presentation, management and outcome of patients with ductal carcinoma in situ (DCIS) with microinvasion (invasion ≤1 mm in size)-results from the UK Sloane Project.
Br J Cancer
; 127(12): 2125-2132, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36224403
7.
Nuclear morphology in breast lesions: refining its assessment to improve diagnostic concordance.
Histopathology
; 80(3): 515-528, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34605058
8.
Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ.
Pathobiology
; 89(6): 382-392, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35533650
9.
PP1, PKA and DARPP-32 in breast cancer: A retrospective assessment of protein and mRNA expression.
J Cell Mol Med
; 25(11): 5015-5024, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33991172
10.
Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases.
Br J Cancer
; 124(11): 1836-1842, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33762723
11.
SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer.
Breast Cancer Res Treat
; 189(2): 317-331, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34282517
12.
Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management.
Histopathology
; 78(5): 759-771, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33113154
13.
Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial.
Lancet Oncol
; 21(9): 1165-1172, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32800099
14.
Retrospective assessment of cyclin-dependent kinase 5 mRNA and protein expression and its association with patient survival in breast cancer.
J Cell Mol Med
; 24(11): 6263-6271, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32352232
15.
Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Breast Cancer Res
; 22(1): 85, 2020 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32782013
16.
Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer.
Br J Cancer
; 122(1): 94-101, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31819174
17.
The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.
Breast Cancer Res Treat
; 181(1): 1-12, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32200487
18.
Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.
Breast Cancer Res Treat
; 182(2): 267-282, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32445177
19.
The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer.
Breast Cancer Res Treat
; 179(1): 79-90, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31599393
20.
A novel prognostic two-gene signature for triple negative breast cancer.
Mod Pathol
; 33(11): 2208-2220, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32404959